Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2022.0309


Pioneering genomic technologies driving transformative cancer research.

Prof. Andreas Sendler, MD, PhD.


The advent and refinement of next generation sequencing (NGS) CRISPR–Cas9 and regulatory genomic network mapping technologies have revolutionized biomedical cancer research. These advances provide promises to overcome current unmet challenges. First, to develop robust biomarkers for tailored treatment in individual patients. Second, to dramatically expand the catalogues of cancer genes and actionable mutations. These advances enhance the potential to improve oncological outcomes.

(Citation: Gastric & Breast Cancer 2022; 17(1): 1-5)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 15 January 2020